Citizens Financial Group Inc. RI Acquires 299 Shares of Insulet Corporation $PODD

Citizens Financial Group Inc. RI raised its holdings in Insulet Corporation (NASDAQ:PODD) by 34.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,169 shares of the medical instruments supplier’s stock after purchasing an additional 299 shares during the period. Citizens Financial Group Inc. RI’s holdings in Insulet were worth $367,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Larson Financial Group LLC increased its stake in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 81 shares during the period. Zions Bancorporation National Association UT acquired a new stake in shares of Insulet during the 1st quarter worth $26,000. SouthState Corp increased its position in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 76 shares during the period. Kozak & Associates Inc. acquired a new stake in Insulet during the second quarter worth about $32,000. Finally, Golden State Wealth Management LLC increased its holdings in Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 69 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PODD. Wolfe Research increased their price target on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research note on Wednesday, October 8th. Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Rothschild & Co Redburn raised their price objective on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Finally, Barclays lifted their target price on Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $376.35.

Insiders Place Their Bets

In other Insulet news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.39% of the company’s stock.

Insulet Trading Up 3.9%

Shares of NASDAQ PODD opened at $346.36 on Thursday. The firm has a 50 day moving average price of $322.93 and a two-hundred day moving average price of $314.19. The stock has a market cap of $24.37 billion, a P/E ratio of 105.28, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.11. The company had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet’s revenue for the quarter was up 29.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.